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We recently described an association between risk of type 2
diabetes and variants in the transcription factor 7-like 2
gene (TCF7L2; formerly TCF4), with a population attributable
risk (PAR) of 17%–28% in three populations of European
ancestry1. Here, we refine the definition of the TCF7L2 type 2
diabetes risk variant, HapBT2D, to the ancestral T allele of
a SNP, rs7903146, through replication in West African and
Danish type 2 diabetes case-control studies and an expanded
Icelandic study. We also identify another variant of the same
gene, HapA, that shows evidence of positive selection in
East Asian, European and West African populations. Notably,
HapA shows a suggestive association with body mass index
and altered concentrations of the hunger-satiety hormones
ghrelin and leptin in males, indicating that the selective
advantage of HapA may have been mediated through
effects on energy metabolism.
We recently reported an association between three markers (the
composite allele X of microsatellite DG10S478 and the T alleles of
SNPs rs12255372 and rs7903146) and type 2 diabetes in Icelanders
and replicated the finding in two additional case-control series of
European ancestry from the USA and Denmark (Denmark A)1. These
markers are located within a 64-kb block of strong linkage disequili-
brium (LD) containing exon 4 and parts of two large flanking introns
of the 217-kb TCF7L2 gene on chromosome 10 (Supplementary
Fig. 1 online), and are highly correlated in populations of European
ancestry. To replicate and refine this association to type 2 diabetes, we
genotyped these markers in 1,149 affected individuals and 2,400
controls in another Danish sample (Denmark B) and in a more
genetically diverse West African group2 consisting of 621 affected
individuals and 448 controls. We also increased the number of
genotyped Icelandic controls from 931 to 9,950. In Denmark B, all
three variants were strongly associated with disease risk. However, the
association of rs7903146 T (relative risk (RR) ¼ 1.49 (95% confidence
interval (c.i.): 1.34–1.66), P ¼ 6.4  10–13, PAR ¼ 21%) was notice-
ably stronger than those of the other two variants (Table 1 and
Supplementary Table 1 online). Haplotypes carrying DG10S478 X or
rs12255372 T but not rs7903146 T did not confer any risk. In contrast,
haplotypes carrying rs7903146 T conferred similar risk regardless of
whether they carried DG10S478 X or rs12255372 T. Comparable
results were obtained with the expanded Icelandic case-control study
(Supplementary Fig. 2 online). In the West African study group,
the association of rs7903146 T to type 2 diabetes was replicated
(RR ¼ 1.45 (1.19–1.77), P ¼ 0.00021, PAR ¼ 20%), after adjusting
for relatedness and ancestry. However, the association was not
significant for DG10S478 X and was weaker for rs12255372 T. Overall,
these results rule out DG10S478 X and rs12255372 T as causal variants
but identify rs7903146 T as either the risk variant itself or its closest
known correlate.
This is consistent with results from recent replication studies, which
have reported slightly higher risk at greater statistical significance for
rs7903146 T (albeit with no formal attempt to evaluate the difference
in effect)3,4. Equally important, these results support the notion that
relatively diverse populations, such as those of West Africa, provide the
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means to refine association signals detected in relatively homogeneous
populations (such as those of European ancestry) characterized by
larger regions of strong LD. Sequencing all exons of TCF7L2 and
B90% of a 120-kb region (114.38–114.5 Mb, NCBI build 34)
spanning the LD block containing rs7903146 did not uncover any
additional variants with a stronger association to type 2 diabetes than
rs7903146 T. Given the pattern of LD surrounding rs7903146 in the
HapMap groups, we conclude that if the T allele is not itself the risk
variant, then the unidentified functional variant it tags is unlikely to lie
outside the aforementioned sequenced region.
A phylogenetic reconstruction of the evolutionary relationships
between haplotypes within the TCF7L2 exon 4 LD block uncovered
two major lineages (Fig. 1). The more diverse lineage, HapB, contains
all but one of the haplotypes carrying rs7903146 T, a subset we refer to
as HapBT2D. The second major lineage, HapA, consists of a relatively
homogeneous cluster of haplotypes, noticeably divergent from HapB,
that show a ‘star-like’ pattern of diversity, with a single basal haplotype
accounting for 81% of its chromosomes. There is an unusual degree of
divergence between the HapMap groups in this genomic region, with
the frequency of HapA ranging from 10% in Nigerian Yoruba (YRI) to
58% in individuals of European ancestry from the Utah pedigree of
the Centre d’Etude du Polymorphisme Humain (CEU) and 95% in
East Asians (CHB+JPT) (Fig. 1). Thus, unlike in populations of
European and African ancestry, rs7903146 T (HapBT2D) cannot
account for a large fraction of type 2 diabetes in East Asian popula-
tions, because its frequency is only B2% in the CHB+JPT HapMap
group. Notably, the pattern of diversity shown in Figure 1 is suggestive
of a positive selective sweep that may have rapidly driven HapA
almost to fixation in East Asians and to lower frequencies in
Europeans and Africans.
To test this hypothesis, we applied two different methods, an
FST-based test and the long-range haplotype (LRH) test
5, to search
for signals of positive selection in the HapMap groups. A history of
positive selection may be indicated for loci where FST, the observed
proportion of the overall genetic variation due to differences between
groups, is in the upper extreme of the range expected under neutral
evolution. Using haplotypes constructed from 42 consecutive SNPs
within the exon 4 LD block, we obtained FST ¼ 0.306 for the three
HapMap groups. Based on 10,000 coalescent simulations (using
demographic settings from ref. 6), it emerged that such a high FST
value is very unlikely under neutral evolution (P ¼ 0.0018). Examina-
tion of FST values between HapMap group pairs showed that the
deviation from neutral expectations is due to the difference between
the East Asian group and the other two (Po 0.002 in both cases, but
P ¼ 0.567 for the difference between the CEU and YRI groups). Using
only rs7924080 T to tag HapA, we obtained FST ¼ 0.7559 for the three
HapMap groups, with only 0.36% of 2,643,043 HapMap SNPs (those
typed in all three groups, polymorphic in at least one and not on the
X chromosome) showing an equal or greater value of FST. These
results are consistent with a positive selective sweep of HapA in East
Asians and no selection (or less intense selection) in the other two
HapMap groups.
When a variant is driven rapidly to high frequency by positive
selection, insufficient time passes for recombination and mutation to
produce the magnitude of genetic diversity expected on the back-
ground of a neutral variant of the same frequency5,7. The LRH test
statistic, relative extended haplotype homozygosity (rEHH), measures
the background diversity of a putative positively selected core haplo-
type relative to the background diversity of other core haplotypes
constructed from alleles of the same loci. We defined core haplotypes
using three SNPs (rs7924080, rs11196199 and rs12255372) spanning a
20-kb region within the exon 4 LD block (rs7924080 efficiently tags
HapA in all HapMap groups). For the three HapMap groups (Fig. 2),
we calculated rEHH at increasing distances (within a 400-kb region)
from the HapA core haplotype and the distribution of rEHH values
expected for equally frequent haplotypes under neutral evolution
(obtained from coalescent simulations based on demographic settings
from ref. 6). Overall, these tests indicate that strong positive selection
drove HapA to near fixation in East Asian populations and that
weaker or shorter selective episodes may also have increased the
frequency of HapA in Europe and Africa. We obtained similar results
when we performed a genome-wide comparison of integrated rEHH
(irEHH) values for HapA with those of equally frequent alleles for
each of the HapMap groups (see Methods). Thus, only 0.7% of
15,497 alleles (East Asians), 7.9% of 17,010 alleles (CEU) and 2.7%
of 42,354 alleles (YRI) had irEHH values greater than or equal to those
observed for HapA, indicating that the signature of positive selection
observed for HapA is unusual in all three HapMap groups when
compared with the rest of the genome, especially in the East Asians.
We obtained rough age estimates for HapA based on its recombina-
tion history8: 11,933, 8,401 and 4,051 years for the CEU, East Asian
and YRI HapMap groups, respectively. Although tentative, these ages
coincide broadly with the onset of agriculture in the three geographic
regions represented by the HapMap groups9.
What was the phenotypic effect of HapA that increased the
reproductive success of its carriers in the past? We previously reported
a suggestive nonsignificant negative association between HapBT2D and
body mass index (BMI) in type 2 diabetes patients1 (see also ref. 3). To
Table 1 Association of type 2 diabetes risk with the markers DG10S478, rs12255372 and rs7903146
Study group (number of affected
individuals/controls)
Marker
(allele)
Frequency in individuals with
type 2 diabetes
Frequency in
controls RR (95%c.i.) P valuea
Denmark B (1,149/2,400) DG10S478 (X) 0.316 0.252 1.37 (1.23–1.53) 2.11  10–8
rs12255372 (T) 0.320 0.256 1.36 (1.22–1.52) 3.37  10–8
rs7903146 (T) 0.345 0.261 1.49 (1.34–1.66) 6.46  10–13
Iceland (1,185/9,950) DG10S478 (X) 0.364 0.288 1.41 (1.28–1.56) 2.35  10–12
rs12255372 (T) 0.363 0.289 1.41 (1.28–1.55) 8.98  10–12
rs7903146 (T) 0.391 0.304 1.47 (1.33–1.62) 5.19  10–15
West Africa: combined (621/448)b DG10S478 (X) - - 1.20 (0.91–1.59) 0.19
rs12255372 (T) - - 1.31 (1.01–1.69) 0.044
rs7903146 (T) - - 1.45 (1.19–1.77) 0.00021
aP values for the Icelandic and the West African studies were adjusted for relatedness of the individuals using simulations. bThe Mantel-Haenszel model was used to combine the results obtained
from the four West African subgroups (results for each subgroup are shown in Supplementary Table 1). As the estimates of RR in the combined West African group are not directly derived from the
allele frequencies in this group, we do not show these frequencies here.
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follow up on these observations, we tested for association of HapA and
HapBT2D to BMI in five diabetes patient groups and six control groups
(Table 2). Here, HapBT2D represents haplotypes that carry rs7903146 T,
whereas HapA represents haplotypes with rs10885406 A and
rs7903146 C. This definition of HapA is almost perfectly correlated
(r2 ¼ 0.96) with that used in the preceding selection analyses in
the combined HapMap data. Combining results from five type 2
diabetes patient groups using the Mantel-Haenszel model, HapA is
associated with increased BMI (1.4% per copy, P ¼ 0.0014), whereas
HapBT2D is associated with decreased BMI (–1.3% per copy,
P ¼ 0.0016). The results for HapA and HapBT2D are not independent,
as about 80% of the haplotypes in populations of European ancestry
are either HapA or HapBT2D. The estimated effect for haplotypes that
are neither HapA nor HapBT2D is intermediate, but there is insuffi-
cient power to distinguish it clearly from the effects of HapA or
HapBT2D. The negative association between HapBT2D and BMI in
affected individuals does not necessarily imply that HapBT2D leads to
reduced BMI, as it could simply reflect the joint independent risk of
BMI and HapBT2D for type 2 diabetes. When we combined results
from the six control groups, we observed a weaker association in the
same direction as in the affected individuals: an increase of 0.39% per
copy of HapA (P ¼ 0.075) and a decrease of 0.44% per copy of
HapBT2D (P ¼ 0.092).
The estimated effects of the haplotypes on BMI are consistently
stronger for male affected individuals (1.9% per copy of HapA;
P ¼ 0.00041) and male controls (0.63% per copy; P ¼ 0.041).
Corresponding results for HapBT2D are –1.8% (P ¼ 0.00049) and
–0.45% (P ¼ 0.18), respectively (Table 2). Overall, the association
between the TCF7L2 variants and BMI seems real, albeit modest in the
controls. Indeed, all reported P values are two-sided and thus slightly
conservative for replication groups, where it may be appropriate to
test only for increased BMI with HapA and decreased BMI with
HapBT2D. We are presently unable to determine whether the effect of
TCF7L2 haplotypes on BMI is driven by HapA or HapBT2D or whether
they exert opposing effects on BMI. Also, there may be differences in
the magnitude of effect among the groups (notwithstanding that some
estimates have large standard errors).
As BMI is a major risk factor for type 2 diabetes, it is intriguing, and
highlights the complexity of the disease10, that HapBT2D is associated
with reduced BMI. This suggests that individuals who acquire type 2
Chimpanzee
HapA
HapB
rs7903146 T
rs7903146 C
JPT
HCB
YRI
CEU
Figure 1 Median-joining (MJ) network30 describing the evolutionary relationships between 78 distinct haplotypes, inferred from the genotypes of 63 SNPs
and one microsatellite (DG10S478) from the TCF7L2 exon 4 LD block. Each haplotype is represented by a circle whose area reflects the overall number of
copies observed and whose color-coding indicates the frequency of the haplotype in the HapMap groups. Lines between circles represent mutational
evolutionary pathways between haplotypes reconstructed by the MJ algorithm; line length is proportional to the number of differences between haplotypes.
Filled squares represent non-sampled haplotypes that were reconstructed by the MJ algorithm as evolutionary intermediaries between observed haplotypes.
The network shows two basic clusters of haplotypes: first, the relatively diverse cluster HapB, to which about 90% of the YRI haplotypes belong. As all the
type 2 diabetes risk haplotypes, now defined by rs7903146 T, also belong to HapB, we refer to this set of haplotypes as HapBT2D (circles with thick
outlines). HapBT2D is not a monophyletic lineage. Indeed, the relatively widespread distribution of rs7903146 T in the network is consistent with it being the
ancestral allele (that is, identical to the chimpanzee reference sequence), with ample time to recombine with a variety of haplotype backgrounds, particularly
in the relatively diverse West African population. The second cluster, HapA, contains a more homogeneous set of haplotypes that show a star-like pattern of
diversity suggestive of a positive selective sweep on a monophyletic lineage. HapA accounts for 10%, 58% and 95% of the YRI, CEU and CHB+JPT
HapMap samples, respectively. The long branch that separates HapA from HapB represents a set of 20 strongly correlated SNPs, any one of which can be
used as a surrogate for HapA.
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diabetes through HapBT2D may have a disease different from that of
those who acquire it through obesity. Conversely, since HapA is
associated with increased BMI, it is legitimate to ask whether HapA
and HapBT2D might be pulling individuals toward opposite ends of a
distribution of physiological function with relation to their impact on
BMI, providing distinct routes toward a common end, type 2 diabetes.
Pooling results from the five diabetes case-control sets, HapA was
estimated to have a slightly, but not significantly, higher risk than
haplotypes that are neither HapBT2D nor HapA (RR¼ 1.06, P¼ 0.22).
Thus, HapBT2D remains the only clear-cut risk factor for type 2
diabetes at this locus.
Given the association of HapA and HapBT2D to BMI in males, and
noting a recent report of lower insulin secretion in HapBT2D carriers
with type 2 diabetes3, we examined their relationship to 14 metabolic
traits in a subset of 918 Icelandic controls. Two of these traits, the
fasting plasma concentrations of the hormones ghrelin and leptin,
showed nominally significant differences (a decrease in the level of
ghrelin and an increase in the level of leptin) by HapA copy number in
males (P ¼ 0.0058 and P ¼ 0.025, respectively; Table 3). A suggestive
increase in the fasting plasma concentration of insulin per HapA copy
was also observed in males (P ¼ 0.09). No such associations were
observed for HapBT2D (Supplementary Table 2 online). While these
results are not significant at the 0.05 level after strict correction for the
number of tests performed, they are suggestive. In particular, given the
stronger association of HapA to BMI in males, it is noteworthy that
the effects are observed only in males.
Ghrelin and leptin are of interest in the context of type 2 diabetes
and the past selective forces that may have acted on variants of TCF7L2
because of their role in the short-term neuroendocrine regulation of
appetite and the long-term regulation of fat storage and energy
metabolism11. In the long-term, fasting concentrations of ghrelin and
leptin are strongly influenced by BMI such that weight gain increases
the basal level of leptin and reduces the basal level of ghrelin12.
Nonetheless, the strongest relationships we observed, HapA with
ghrelin and the ghrelin-to-leptin ratio (GLR) in males, remain nomin-
ally significant even when adjusted for the impact of BMI (P ¼ 0.015
and P ¼ 0.016, respectively), whereas the weaker relationship between
HapA and BMI disappears when adjusted for the impact of these traits.
Further studies are needed to confirm the impact of HapA on
energy metabolism and to determine whether this phenotype con-
tributed to the enhanced fitness of HapA in the past. Indeed, TCF7L2
encodes a transcription factor and might thus influence multiple
Figure 2 The LRH selection test at increasing physical distance from the
core haplotype region. Shown are (a) YRI, (b) CEU and (c) East Asian
HapMap groups. The solid line denotes observed rEHH values for HapA. The
broken lines denote the 0.025, 0.25, 0.5, 0.75 and 0.975 quantiles from
the distribution of rEHH values expected under neutral evolution, based on
at least 5,000 coalescent simulations for each HapMap group. Simulations
were conditioned on SNP minor allele frequencies, estimated recombination
rates28 and best-fit demographic settings6 for the HapMap groups. Only
simulated data sets that yielded a core haplotype at the same frequency as
HapA in the three HapMap groups (0.10, 0.58 and 0.95, respectively) were
considered. P values indicate the rank percentile of the observed aggregate
rEHH value among the expected aggregate values. All three groups show
significant P values in the region to the left of the core haplotype region, although the deviation from neutral expectations is marginal for the CEU sample.
Only the East Asian group yielded a significant P value to the right of the core haplotype region. Similar results were obtained using neutral simulations
based on other standard demographic models (Supplementary Fig. 3 online).
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Table 2 Association of HapA and HapBT2D with BMI
a in individuals with type 2 diabetes and controls
Individuals with type 2 diabetes Controls
HapBT2D HapA HapBT2D HapA
Cohort
Subgroup (affected
individuals/controls) Effect (s.e.m.) P value Effect (s.e.m.) P value Effect (s.e.m.) P value Effect (s.e.m.) P value
Iceland Both sexes (1,146/9,222) –0.015 (0.007) 0.036 0.021 (0.007) 0.0024 –0.0049 (0.0039) 0.21 0.0058 (0.0035) 0.094
Males (676/3,992) –0.014 (0.008) 0.080 0.018 (0.008) 0.026 –0.0037 (0.0049) 0.45 0.0069 (0.0044) 0.12
Philadelphia Both sexes (326/497) –0.002 (0.013) 0.88 0.007 (0.014) 0.63 –0.0145 (0.0138) 0.29 0.0163 (0.0123) 0.19
Males (230/310) 0.001 (0.014) 0.94 0.005 (0.015) 0.76 –0.0123 (0.0167) 0.46 0.0091 (0.0145) 0.53
Denmark A Females (227/507) 0.014 (0.014) 0.31 –0.005 (0.013) 0.71 –0.0054 (0.0113) 0.63 0.0106 (0.0105) 0.31
Denmark B Both sexes (1,129/2,400) –0.029 (0.008) 0.00017 0.018 (0.007) 0.016 –0.0016 (0.0048) 0.73 0.0006 (0.0043) 0.88
Males (684/1,138) –0.035 (0.009) 0.00011 0.028 (0.009) 0.0013 –0.0007 (0.0062) 0.91 0.0012 (0.0055) 0.83
West Africa Both sexes (621/439) –0.002 (0.011) 0.86 –0.013 (0.018) 0.49 –0.0296 (0.0148) 0.045 0.0220 (0.0224) 0.32
Males (364/262) –0.006 (0.014) 0.66 –0.006 (0.024) 0.79 –0.0332 (0.0201) 0.10 0.0570 (0.0294) 0.055
Germanyb Both sexes (0/1942) – – – – 0.0001 (0.0071) 0.99 –0.0027 (0.0063) 0.67
Males (0/950) – – – – –0.0074 (0.0091) 0.41 0.0106 (0.0080) 0.19
Combined Both sexes (3,449/15,007) –0.0133 (0.0042) 0.0016 0.0139 (0.0044) 0.0014 –0.0044 (0.0026) 0.092 0.0039 (0.0022) 0.075
Males (1,954/6,652) –0.0180 (0.0052) 0.00049 0.0190 (0.0054) 0.00041 –0.0045 (0.0034) 0.18 0.0063 (0.0031) 0.041
aMultiple regression was performed on log-transformed BMI values. bA test of transmission disequilibrium was performed for HapA and HapBT2D in 985 German family trios with morbidly obese
children (of which 446 involved only obese boys), uncovering a slight excess in the transmission of HapA to the obese children (P ¼ 0.44 for both sexes and P ¼ 0.1 for just boys). Conversely,
there was a slight deficit in the transmission of HapBT2D to the obese children (P ¼ 0.3 for both sexes, P ¼ 0.045 for boys only). P values are two-sided in each instance.
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phenotypic traits. However, variation in energy metabolism must have
been important for survival throughout human evolution, and it may
be more than coincidence that the age of HapA in each of the
HapMap groups coincides approximately with the transition to
agriculture—a move that may have brought serious nutritional
challenges along with the rewards. Whether the selective advantage
of HapA acted through effects on energy metabolism, we note that our
findings contradict a key prediction of the thrifty-genotype hypoth-
esis13, insofar as HapBT2D, a major genetic risk factor for type 2
diabetes, is negatively associated with BMI and is not the variant that
contributed to adaptive evolution in the recent past.
METHODS
Genotype data. TCF7L2 spans a 217-kb region on chromosome 10
(114374798–114592005, NCBI build 34), and its product is a high-mobility
box–containing transcription factor that has a role in the Wnt signaling
pathway and in type 2 diabetes. Our analyses are based on 348 SNPs from
release 19 of the HapMap data that spanned the region 114200000 to
114620000 (420 kb) and were polymorphic in at least one of the four HapMap
groups. To these data, we added 13 SNPs (which we had identified through
sequencing and genotyped) and one microsatellite, DG10S478. As in our
previous publication1, allele X of DG10S478 is defined as all alleles larger than
0. All of these loci are contained within region 114397469–114489563 on
chromosome 10, NCBI build 34. Out of the total of 361 SNPs, 236 were
polymorphic in the combined East Asian group, 298 were polymorphic in the
YRI group and 276 were polymorphic in the CEU group. Supplementary
Figure 1 shows the LD structure in the CEU, YRI and East Asian HapMap
groups across a 545-kb region of chromosome 10 that contains the TCF7L2
gene, and it shows the distribution of SNPs across the region and the relative
positions of introns and exons.
Phased haplotypes were generated for the 60 CEU parents, 60 YRI parents
and 90 East Asian individuals from the HapMap project. The phase of alleles in
haplotypes was estimated using the EM algorithm14, in combination with the
family trio information for the CEU and YRI groups (where the genotypes
from the 30 children in each of the groups were used to help infer the allelic
phase of the haplotypes). To obtain haplotypes across the entire 420-kb region,
phase was estimated in informative multiple overlapping segments, using an
approach analogous to that applied in the phasing of entire chromosomes by
the HapMap project15.
New case-control groups used for type 2 diabetes association refinement
studies. Three type 2 diabetes case-control data sets were used to replicate and
refine the association initially detected in ref. 1. First, the Africa America
Diabetes Mellitus study, which was originally designed as an affected sibling
pair study with enrollment of available spouses as controls. It has since been
expanded to include other family members of the affected pairs and population
controls. Recruitment strategies and eligibility criteria for the families enrolled
in this report have been described previously1. This West African case-control
series consisted of individuals from the Yoruba (156 affected individuals,
250 controls) and Igbo (186 affected individuals, 113 controls) groups from
Nigeria and the Akan (196 affected individuals, 54 controls) and Gaa-Adangbe
(83 affected individuals, 31 controls) groups from Ghana, which have pre-
viously shown little evidence of significant population substructure16.
The second set of individuals with type 2 diabetes were from the Steno
Diabetes Center in Copenhagen (N ¼ 1,018) and from the Inter99 population-
based sample of 30- to 60-year-old individuals living in the greater Copenhagen
area and sampled at Research Centre for Prevention and Health17 (N ¼ 359).
This data set is referred to in the text as Denmark B. Diabetes and pre-diabetes
categories were diagnosed according to the 1999 World Health Organization
(WHO) criteria. A total of 1,149 of these individuals were genotyped. An
effectively random subset (N ¼ 2,400) of Danish controls with BMI measure-
ments were obtained from the Inter99 collection. Informed written consent was
obtained from all subjects before participation. The study was approved by the
Ethical Committee of Copenhagen County and was in accordance with the
principles of the Helsinki Declaration.
The third set of affected individuals with type 2 diabetes from Iceland was
described previously1 and was analyzed together with an expanded set of
controls described in the next section.
Cohorts used to assess association to BMI. Descriptive statistics in this section
are presented as mean ± s.d., with age measured in years and BMI measured in
kg/m2. The Icelandic BMI cohort (N ¼ 9,222; age ¼ 61.2 ± 16.6; BMI ¼ 27.4 ±
5.2) was composed of individuals who participated in studies of the genetic
etiology of cardiovascular and metabolic diseases. Most subjects were recruited
as unaffected relatives of probands or as controls and did not have any history
of cardiovascular diseases (CVD). Detailed information was gathered for all
individuals who participated in these studies, including biometric obesity and
fasting concentration of blood lipids and glucose. A familial-enriched subset of
the CVD cohort (N ¼ 918), selected for use in gene expression studies, was
extensively measured for clinical markers, including fasting concentrations of
ghrelin and leptin. The German control cohort was composed of unrelated
underweight, normal-weight and obese students (N ¼ 558; age ¼ 24.97 ± 3.55;
BMI¼ 20.93 ± 4.44) and unrelated parents of obese children (N ¼ 1384; age ¼
42.75 ± 5.89; BMI ¼ 30.40 ± 6.16), as detailed in ref. 18. The parents belong to
708 independent German families containing at least one obese child (BMI ¼
31.03 ± 5.95; age 14.02 ± 3.71). The association between TCF7L2 variants
Table 3 Association of HapA with 14 phenotypic traits linked to energy metabolism in Icelandic controls
Both sexes (N ¼ 918) Males (N ¼ 419) Females (N ¼ 499)
Trait Effect (s.e.m.) P valueb Effect (s.e.m.) P valueb Effect (s.e.m.) P valueb
Percentage body fat 0.195 (0.474) 0.68 1.498 (0.796) 0.06 –1.006 (0.574) 0.08
Waist-hip ratio 0.002 (0.004) 0.64 –0.003 (0.006) 0.62 0.006 (0.006) 0.28
Systolic blood pressurea 0.004 (0.007) 0.58 0.001 (0.009) 0.89 0.006 (0.009) 0.51
Diastolic blood pressure 0.668 (0.493) 0.18 0.236 (0.691) 0.73 1.074 (0.687) 0.12
Total cholesterola –0.002 (0.010) 0.81 0.013 (0.014) 0.33 –0.017 (0.014) 0.22
High-density lipoproteina –0.002 (0.013) 0.86 –0.016 (0.016) 0.30 0.011 (0.019) 0.58
Low-density lipoprotein –0.009 (0.050) 0.86 0.056 (0.070) 0.43 –0.068 (0.068) 0.32
Triglyceridea 0.012 (0.027) 0.65 0.055 (0.039) 0.16 –0.027 (0.035) 0.45
Glucose –0.003 (0.008) 0.69 –0.014 (0.011) 0.18 0.007 (0.010) 0.48
Creatinine 0.457 (0.613) 0.46 0.844 (0.931) 0.36 0.106 (0.779) 0.89
Insulina 0.065 (0.037) 0.076 0.093 (0.055) 0.090 0.041 (0.048) 0.40
Leptina 2.206 (2.723) 0.42 6.977 (3.111) 0.025 –2.082 (4.057) 0.61
Ghrelina –0.056 (0.033) 0.086 –0.116 (0.042) 0.0058 –0.003 (0.046) 0.95
Ghrelin-leptin ratio (GLR)a –0.115 (0.069) 0.10 –0.281 (0.108) 0.0092 0.032 (0.081) 0.69
aValues for these traits were log-transformed for the association analysis. bP value adjusted for relatedness of individuals by simulations through population-wide genealogies.
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and BMI was also assessed in type 2 diabetes case-control groups from
Denmark and Pennsylvania, both of which were described and analyzed in
our previous publication1.
Active ghrelin was measured in a set of 918 Icelandic population controls
using ELISA (sensitivity was 2.5 fmol/ml) from Linco Research. Leptin was
measured using ELISA (sensitivity at least 7.8 pg/ml) from R&D systems. All
samples, standards, two controls (high and low) and unknown treated plasma
samples were measured in duplicate. Blood lipids, glucose and other biomar-
kers were measured as previously described19.
Analysis of association to diabetes. We used a likelihood ratio test to
calculate two-sided P-values for single-marker association to type 2 diabetes.
For the Denmark B case-control study, we attempted to genotype all individuals
reported in Table 1 for DG10S478, rs12255372 and rs7903146. The average
yield was about 96%. As the markers were in strong LD, when the genotype
of one marker was missing for an individual, the genotypes of the other
two markers were used to provide partial information through a likelihood
approach we have described and used previously20. This ensured that results
for all three markers presented in Table 1 were always based on the same
individuals, allowing meaningful comparisons. The average yield of the three
markers was about 89% for the West African study, and we used the
same method to handle missing genotypes. Allele frequencies rather than
carrier frequencies are presented for the markers. Allele-specific RR was
calculated assuming a multiplicative model21. The results for the West
African study were obtained by combining data and results from four
ethnic groups using a Mantel-Haenszel model22 in which each group was
allowed to have different population frequencies for alleles, but alleles
were assumed to have identical relative risks. Standard errors and confidence
intervals were computed assuming that the log of the estimate of RR has a
normal distribution.
Correction for relatedness. We tested the association of an allele to diabetes
using the signed (‘+’ for excess and ‘–’ for deficit in affected individuals) square
root of a standard likelihood ratio statistic that has an asymptotic standard
normal distribution under the null hypothesis when subjects are unrelated.
However, some of the individuals in the Icelandic and West African case-
control groups were related to each other (see above). The genotypes of closely
related individuals are not independent, causing the s.d. of the aforementioned
association test statistic to be 41, which, if not corrected for, would lead to
P values that are anticonservative. An adjustment for relatedness was performed
using a previously described procedure1,20. In short, we performed 100,000
simulations that took into account the known relationships of the individuals
to obtain the actual s.d. of the test statistic under the null hypothesis of
no association.
Analysis of association to BMI and metabolic traits. The association between
BMI and HapA or HapBT2D was analyzed using multiple regression. Log(BMI)
was taken as the response variable. The estimated number of copies of HapA
(or HapBT2D) carried by an individual was entered as an explanatory variable.
Adjustment for sex and age was accomplished by including sex (1 + age + age2)
as explanatory variables in analyses that combined data from both sexes.
Analyses for males included age and age2 as explanatory variables. For the West
African cohort, indicator variables for the different ethnic groups were also
included as explanatory variables. Our haplotype analysis program NEMO23
(which implements methods based on maximum likelihood) was used to
estimate of number of copies of HapA or HapBT2D carried by individuals.
Because of the strong LD between rs10885406 and rs7903146, the two SNPs
used to define HapA, there is little uncertainty in phase for most individuals.
Results from different cohorts were combined using a Mantel-Haenszel-like
model22. Specifically, for testing, a weighted average of the t statistics was
calculated using weights proportional to the inverse of the standard errors of
the estimated effects. The combined estimated effect was computed as a
weighted average of the individual estimated effects using weights proportional
to the inverse of the standard errors squared. Missing genotypes and correction
for relatedness of individuals were performed using methods like those we
described above for the diabetes association analysis. Similar association
analyses were performed for other metabolic traits.
Alignment of the human and chimpanzee reference sequences. An alignment
of the reference human and chimpanzee sequences, between positions
114274597 and 114674597 (NCBI human build 34) was obtained from the
Ensembl genome browser. This alignment was used to determine the ancestral
allelic states of the SNPs from the HapMap project, the SNPs typed by us and
the microsatellite DG10S478.
Statistical tests of positive selection. Evidence for the impact of natural
selection on the TCF7L2 exon 4 LD block was examined by applying two
different methods to the HapMap project groups. In these analyses, the
Japanese (JPT) and Chinese (CHB) HapMap groups were combined to form
a single East Asian group (CHB+JPT). First, we examined whether the degree
of population divergence in haplotype frequencies among the HapMap groups
exceeded expectations based on neutral evolution for the exon 4 LD block.
Under neutrality, allele and haplotype frequency differences between popula-
tions are shaped by the counteracting forces of genetic drift, gene flow and
mutation. The range of expected outcomes is constrained by the demographic
history experienced by the populations. Thus, when the observed divergence
between populations is in the upper extreme of the expected range (or outside
it), the neutral model can be rejected in favor of one in which population
differences in the intensity selective forces have caused an unusual degree of
divergence in the frequency of particular variants24. In cases where positive
selection has driven a variant to high frequency in a subset of the populations
tested, it is expected that unusually great divergence between populations will
be accompanied by unusually small variation within the populations that
have experienced the most selection. We used the analysis of molecular
variance (AMOVA)25 approach to calculate the distribution of genetic
diversity within and among populations in terms of haplotype frequencies.
The expected range of divergence between populations can be determined
either by means of a comparison with a large set of putatively neutral genomic
regions from the same set of samples or by means of a comparison with
multiple simulated data sets. The latter approach is more effective when dealing
with haplotype data from LD blocks. On the one hand, it would be hard to
match comparative data from other parts of the genome with relation to
recombination rates. On the other hand, there is reason to believe that genomic
regions within LD blocks are more gene-rich and therefore less likely to have
experienced neutral evolution than regions that have weaker LD15. Coalescent
simulations were performed to evaluate the statistical significance of the
observed FST values, when controlling for demography, recombination rates
and minor allele frequencies of SNPs. The SNPs used for the FST selection test
are listed in Supplementary Table 3 online.
The second method used to detect signals of positive selection in TCF7L2 is
based on examining the pattern of diversity within populations. Under
neutrality, there is an expected positive relationship between the frequency of
an allele or haplotype, its age, the variability at linked sites and the extent to
which linkage disequilibrium (LD) with other loci decays at increasing physical
distance. Common alleles or haplotypes with unusually low diversity at linked
sites and/or slow decay of LD with increasing physical distance represent likely
targets of recent positive selection5,7. According to this scenario, a variant is
driven so rapidly to high frequency by positive selection that insufficient time
has passed for the accumulation of background mutational and recombina-
tional diversity expected for a neutral variant with the same frequency. We used
the long-range haplotype (LRH) test5 to examine the decay of LD at increasing
distance from HapA, defined with the boundaries of the exon 4 LD block (the
core haplotype area). This test is based on the estimation of the relative
extended haplotype homozygosity (rEHH), which measures the fragmentation
of a putative selected haplotype, caused by recombination and mutation,
relative to other haplotypes made up of alleles from the same loci, as the LD
to increasingly distant loci is assessed.
An advantage to the rEHH statistic is that it evaluates the extended LD
around a putative selected haplotype in relation to the most informative
comparative data: namely, other haplotypes formed by alleles from the same
loci in the same samples5. In order to determine whether the observed pattern
of genetic diversity at TCF7L2 could have been generated by neutral evolution,
we performed coalescent simulations as described below. In order to determine
whether the observed rEHH values could have been produced by the demo-
graphic scenarios tested, we summed rEHH values from the observed data
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across the genomic region examined and compared this aggregate rEHH value
with a null distribution obtained from multiple coalescent simulations. The
proportion of simulations that yield aggregate rEHH values greater than or
equal to the observed value can be used as an empirical P value with which to
evaluate the null hypothesis.
We also sought to determine the rank of rEHH values obtained for variants in
TCF7L2 in a particular HapMap group relative to an empirical distribution of
rEHH values obtained for all other SNP alleles of identical frequency in the same
HapMap group. These calculations were performed using release 19 of the
HapMap data (http://www.hapmap.org). To simplify comparisons between
different genomic regions, we calculated a single integrated rEHH value for
each allele (using an approach similar to ref. 8). The resulting integrated rEHH
(irEHH) value represents the area beneath the line defined by the rEHH point
estimates that are obtained as haplotypes are extended in both directions from
the allele being tested (until the EHH value in both directions has fallen below
0.05). In order to make comparisons of irEHH values meaningful between
regions with different rates of recombination, the positions of SNPs were defined
in cM for these calculations (using recombination rate maps for phase I of the
HapMap that were interpolated for the phase II HapMap data). Although a
genome-wide distribution of irEHH values cannot be considered an appropriate
null distribution to test for signals of positive selection8,26, the rank of a
particular irEHH value in the overall distribution does provide a valuable
indication of how unusual the underlying pattern of diversity is in the genome.
A rough estimate of the age of a selected haplotype was obtained using the
approach described in ref. 8, based on the formula EHH ¼ e2rg , where EHH
represents the probability that two randomly picked chromosomes are homo-
zygous at a recombination distance r from a core haplotype region, given a
common ancestor g generations ago. We assume a generation interval of
25 years. The age of the putative selected haplotype, HapA, was estimated only
for the upstream region that showed the strongest signal of selection and was
based on the average number of generations obtained for EHH values between
0.05 and 0.1.
Coalescent simulations. The Simcoal simulation software27 was used to
generate samples under the neutral coalescent in order to evaluate the statistical
significance of values obtained from selection tests for the observed data. A
major complication in the use of coalescent simulations to detect signals of
natural selection in genetic data is that a population’s demographic history has
a major impact on the expected patterns of diversity within its gene pool. In
particular, it is difficult to distinguish between the impact of a positive selective
sweep at a locus and the impact of a rapid population expansion. In most
previous studies that have used a coalescent-based approach, the solution to
this problem has been to simulate genetic data under a relatively wide range of
demographic scenarios (typically, constant size, population expansion and
bottleneck with expansion) that could be thought to apply to the population
from which the observed data was obtained. We follow this procedure using
three simple models: constant size at Ne ¼ 10,000, a recent instantaneous
expansion from 10,000 to 10,000,000 (200 generations ago) and a dramatic
bottleneck taking Ne from 10,000 to 800 (800 generations ago), a condition that
lasts for 160 generations, after which there is a re-expansion of Ne to 10,000. We
also applied demographic settings obtained from an important recent study6,
wherein a wide range of demographic parameter values for populations of
African, European and East Asian ancestry was evaluated using the genome-
wide collection of SNP genotypes from the HapMap project with the aim of
identifying the best-fitting demographic settings. The latter are referred to
throughout the text as the ‘best fit’ demographic model and are listed in
Supplementary Table 4 online.
Recombination rates between adjacent loci are also key parameters in
coalescent simulations involving multiple linked loci. We set recombination
rates between adjacent SNPs within TCF7L2, according to values available from
HapMap project website. These recombination rates were inferred on the basis
of a population genetics approach28 using release 16c of the HapMap data,
which contained roughly 25% of the SNPs available in release 19. We note that
the direct estimates of recombination rates between microsatellites in the
deCODE genetics map29 are very similar to the inferred rates from the HapMap
data for this region. Additional SNPs from release 19 of the HapMap and other
SNPs genotyped by us were incorporated into the existing recombination map
by means of interpolation using the physical map positions of the SNPs. The
resulting recombination map is shown in Supplementary Table 5 online.
Note: Supplementary information is available on the Nature Genetics website.
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